source
- FDA grants accelerated approval to Tudriqev viral therapy for PD-1-refractory advanced melanomaThe U.S. Food and Drug Administration has granted accelerated approval to Tudriqev (vusolimogene oderparepvec-wtpg), a genetically engineered oncolytic viral therapy for patients with advanced, tre…
- OKYO Pharma CSO Raj Patil boosts stake to 20,030 sharesOKYO Pharma, a clinical stage biotech focused on neuropathic corneal pain and anterior segment eye diseases, disclosed that its chief scientific officer, Raj Patil, PhD, bought additional shares.…